Risankizumab

Status:
Do Not Prescribe (DNP), Red
Decision Date:
September 2019
 

Comments

RED:

  • NICE TA596 - treatment of moderate-to-severe plaque psoriasis
  • NICE TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (Decision date - August 2022)

 

DNP: Moderate-to-severe Crohn's disease. Awaiting national guidance. (Decision date - February 2022)

CCG commissioned 

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app